Supernus制药(SUPN)

34.11 0.37 1.0966%

今开:33.84昨收:33.74
最高:34.39 最低:33.47
涨停价:0.0跌停价:0.0
总市值:1.867009349E9

Supernus制药的热门讨论

持股变动声明

Supernus制药(SUPN)03-23 05:05

$Supernus制药(SUPN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-037934  Size: 8 KB 网页链接查看全文

持股变动声明

Supernus制药(SUPN)03-26 05:05

$Supernus制药(SUPN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-038482  Size: 9 KB 网页链接查看全文

持股变动声明

Supernus制药(SUPN)03-22 05:05

$Supernus制药(SUPN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-037376  Size: 9 KB 网页链接查看全文

持股变动声明

Supernus制药(SUPN)03-15 05:05

$Supernus制药(SUPN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-034563  Size: 9 KB 网页链接查看全文

持股变动声明

Supernus制药(SUPN)03-16 06:45

$Supernus制药(SUPN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-035104  Size: 15 KB 网页链接查看全文

证券出售报告

Supernus制药(SUPN)03-20 04:25

$Supernus制药(SUPN)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-002511  Act: 33  Size: 7 KB 网页链接查看全文

证券出售报告

Supernus制药(SUPN)03-14 04:25

$Supernus制药(SUPN)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-002256  Act: 33  Size: 6 KB 网页链接查看全文

证券出售报告

Supernus制药(SUPN)03-13 04:35

$Supernus制药(SUPN)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-002196  Act: 33  Size: 5 KB 网页链接查看全文

持股变动声明

Supernus制药(SUPN)03-01 06:05

$Supernus制药(SUPN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-029434  Size: 9 KB 网页链接查看全文

持股变动声明

Supernus制药(SUPN)03-01 06:05

$Supernus制药(SUPN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-029432  Size: 9 KB 网页链接查看全文

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43

Supernus制药的最新讨论

逍遥投资派2023-05-26 23:16

$Supernus制药(SUPN)$ 5年来营收除2019年外增长了4年,平均增速17%,营业利润反而在增长3年后,2021年大幅下滑54.7%,2022年继续大幅下滑42.6%,主要是由营业费用暴增引起的。
查了一下资产负债表,果然2021年商誉从4.42亿增加到9.02亿,这次收购使公司的运营效率大幅下滑,至今未缓过来。
查看全文

SeekingBiotech2022-10-10 23:43

SUPN receives CRL for the SPN-830 NDA/阿扑吗啡注射液/改良新药
$Supernus制药(SUPN)$查看全文

王隽2022-03-07 23:08

$Supernus制药(SUPN)$
这世界都疯了
我看他有搞头
[吐血][吐血][吐血][吐血][吐血]查看全文

chuminhua2021-10-12 15:29

10月11日,Supernus Pharmaceuticals同意以每股8.10美元的现金,或约4亿美元收购Adamas制药公司,获得两种获准用于帕金森病患者的药物。该交易还包括两项或有价值权(CVR),其总价值为每股1美元的现金,或约5000万美元。最初的现金对价比Adamas公司10月8日的收盘股价溢价约75%。
该交易将为Su...查看全文

chuminhua2021-04-08 15:00

4月2日,Supernus公司宣布,FDA已批准该公司Qelbree(viloxazine缓释胶囊) 上市,用于治疗6-17岁儿童注意力缺陷多动障碍(ADHD)。Qelbree是近10年来FDA批准的首个新型非兴奋剂类ADHD药物。 Qelbree是一种具有选择性5-羟色胺调节活性的去甲肾上腺素再摄取抑制剂(NET),这一药物已在欧洲作为抗抑郁药...查看全文

BioNews | Supernus:FDA批准SPN-812治疗注意力缺陷型多动症

蹊之美股生物医药2021-04-05 19:45

作者:Kirkland Hwang
微信公众号:蹊之美股生物医药 / CaesarBiotech
标的公司:Supernus Pharmaceuticals Inc.(NASDAQ:SUPN)
• Qelbree(维洛沙嗪缓释胶囊)代表了十年来第一个非刺激性治疗注意力缺陷型多动症(ADHD)的新方法
Supernus制药公司(Supernus Pharmaceutic...查看全文

Takeabreak2021-03-02 11:00

$Supernus制药(SUPN)$ 价值出现了,贪心一下,等21查看全文

t2o22021-02-23 07:35

仔细研究了一下财报发现,公司的现金以各种形式躺在账上,估计今年还会继续收购新公司。$Supernus制药(SUPN)$查看全文

1 2 3

Supernus制药的公告

$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-11-06 AccNo: 0001104659-18-066367 Size: 252 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接

$Supernus Pharmaceuticals, Inc.(SUPN)$ 美东时间 2018-11-06 盘后 披露财报,预期EPS 0.44 网页链接

$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-10-25 AccNo: 0001104659-18-063964 Size: 44 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接

$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-09-21 AccNo: 0001104659-18-057845 Size: 42 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接

$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-09-18 AccNo: 0001104659-18-057416 Size: 59 KBItem 1.01: Entry into a Material Definitive AgreementItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接

$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-09-07 AccNo: 0001104659-18-055660 Size: 47 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接

$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-09-04 AccNo: 0001104659-18-055089 Size: 58 KBItem 7.01: Regulation FD DisclosureItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接

$Supernus Pharmaceuticals, Inc.(SUPN)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-08-09 AccNo: 0001104659-18-050920 Size: 6 MB 网页链接

$Supernus Pharmaceuticals, Inc.(SUPN)$ 8-K - Current report Filed: 2018-08-07 AccNo: 0001104659-18-050207 Size: 266 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接

$Supernus Pharmaceuticals, Inc.(SUPN)$ 美东时间 2018-08-07 盘后 披露财报,预期EPS 0.44 网页链接

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68